AstraZeneca's Tozorakimab Shows Strong Results in COPD Trials
AstraZeneca (AZN) has reported positive results from two late-stage trials of its experimental drug tozorakimab for chronic obstructive pulmonary disease. The biologic reduced moderate and severe flare-ups by approximately 30%, with a strong reduction observed in patients with high eosinophil levels, potentially offering broader access than current treatments. The success reinforces AstraZeneca's forecast that the drug could generate over $5 billion annually at peak sales. It is currently under FDA priority review, with an expected decision by early 2027. The results support the company’s respiratory growth strategy and its goal of reaching $80 billion in annual revenue by 2030. However, regulatory approval remains a key hurdle before commercialization can begin. Additionally, AstraZeneca must demonstrate how tozorakimab will differentiate itself from existing biologics like Dupixent or Nucala and gain physician adoption.
